H.C. Wainwright says the bar is set for oral GLP-1s following this morning’s type 2 diabetes data from Eli Lilly (LLY). The firm continues to expect Viking Therapeutics (VKTX) to “differentiate” with ...

H.C. Wainwright analyst Amit Dayal lowered the firm’s price target on ClearSign (CLIR) to $2 from $6 and keeps a Buy rating on the shares. The ...

Fintel reports that on April 9, 2025, HC Wainwright & Co. initiated coverage of vTv Therapeutics (NasdaqCM:VTVT) with a Buy ...

H.C. Wainwright lowered the firm’s price target on Transcode Therapeutics (RNAZ) to $10 from $20 and keeps a Buy rating on the shares. The firm ...

Highlights,Cabaletta Bio receives a favorable evaluation from HC Wainwright.,An institutional review brings renewed focus to the asset.,The event adheres to common market appraisal procedures.,Within ...

Fintel reports that on April 9, 2025, HC Wainwright & Co. downgraded their outlook for Rallybio (NasdaqGS:RLYB) from Buy to ...

Research analysts at HC Wainwright lowered their Q1 2025 EPS estimates for Genelux in a report released on Monday, March 31st. HC Wainwright analyst E. Bodnar now expects that the company will post ...

HC Wainwright lifted their Q1 2025 EPS estimates for Spectral AI in a note issued to investors on Wednesday, April 2nd. HC ...

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $10 price ...

Fintel reports that on March 7, 2025, HC Wainwright & Co. initiated coverage of Surf Air Mobility (NYSE:SRFM) with a Buy recommendation. As of March 4, 2025, the average one-year price target for ...

Fintel reports that on April 11, 2025, HC Wainwright & Co. initiated coverage of Richtech Robotics (NasdaqCM:RR) with a Buy recommendation. There are 35 funds or institutions reporting positions ...